CAPA news

CAPA and the Arthritis Society CADTH Submission on Upadacitinib for Psoriatic Arthritis

In preparation for the CADTH submission for a manufacturer’s drug Upadacitinib for the treatment of psoriatic arthritis (PsA), the Canadian Arthritis Patient Alliance (CAPA) and the Arthritis Society (TAS) developed a survey to hear directly from people living with psoriatic arthritis about their experiences with these conditions and any experi

With These Hands

Arthritis has inspired artwork by fibre artist, Karen D. Miller. She developed “With these hands” to convey the ability – not the disability – of CAPA Board member Laurie Proulx. Read a few words from the artist about what this piece means to her. “This is a piece that I originally finished in 2015, but  over the [&hell

CAPA, Arthritis Society and Cassie & Friends CADTH Submission on Anakinra (Kineret) for Still’s and SJIA

In preparation for the CADTH submission for a manufacturer’s drug Anakinra (Kineret) for the treatment of Still’s disease in children and adults, the Canadian Arthritis Patient Alliance in collaboration with the Arthritis Society and Cassie and Friends developed a survey to hear directly from people living with Still’s disease and SJIA ab

CAPA Letter on NACI’s Recommendations on Approved COVID-19 Vaccines for People with Autoimmune Disease

The National Advisory Committee on Immunization’s (NACI’s) issued recommendations on the currently approved COVID-19 vaccines.  As individuals who live with autoimmune disease and who are on immunosuppressant therapies, we ask that Committee to consider our perspectives and preferences in NACI's continued updates to the recommendations and as

What is Health Technology Assessment?

Are you wondering what is health technology assessment? Who is responsible for health technology assessment and how do health technology assessment organizations make their decisions? Learn more about it here.

Call for Patient Input on Anakinra for Still’s disease and SJIA Submission

Do you or a family member have Still’s disease or Systemic Idiopathic Juvenile Arthritis (SJIA)? If so, your valuable input is needed to the Common Drug Review (CDR) on the manufacturer’s submission for Anakinra (Kineret) for the treatment of Still’s disease and SJIA in adults and pediatric patients aged 8 months and older!

Your Input Needed to Submission for Upadacitinib for the treatment of PsA

The Common Drug Review (CDR) is welcoming patients to provide input to patient organizations on the manufacturer’s submission for upadacitinib for the treatment of psoriatic arthritis (PsA). Please be one of the first respondents to this survey available in English and French!

Meet CAPA Board member – Therese Lane

“I like living in a solution instead of a problem”. We invite you to listen to CAPA's one of the new Board members, Therese Lane's compelling story of living with arthritis and what made her become the patient advocate!

CAPA newsletters

Newsletter – January 2022

Welcome to 2022! "2022 is feeling a lot like 2021!" said CAPA President Linda Wilhelm. January 2022 had been a busy start of the new year for CAPA team, as we have been engaged in providing patient input to CADTH submission for new lupus drug, preparing for a poster presentation at the CRA annual meeting and many more.

Newsletter – November 2021

This month CAPA has been participated in numerous events in support of the National Pain Awareness Week. Learn what we have done by reading our newsletter!

Newsletter – October 2021

CAPA had been busy with various activities over the month of October including involvement in the release of the Baring It All final report, Fashion Show, compiling information on the 3rd dose vaccine access in provinces and many more.

Newsletter – September 2021

Over the summer, CAPA had participated in the development of a CRA virtual care statement, voiced the patient perspective on proposed drug pricing changes on patients and did an extensive survey on sexual and reproductive health in collaboration with other patient groups. We had planned lots of fun activities for September, the Arthritis Awareness month!

Newsletter – June 2021

This month, CAPA team has been involved in the development of the video on a biosimilar medication. launching the new parenting resources, speaking at the webinar on an action plan for pain in Canada and many more!

Newsletter – May 2021

This month CAPA team has been busy advocating for the second dose of the COVID-19 vaccine for people with autoimmune rheumatic conditions, updating and launching our pregnancy resources and being at the forefront of "A call for action to #PrioritizePain" campaign. Learn more by reading our newsletter!

Newsletter – April 2021

In this newsletter edition, we invite you to provide input to the three very important surveys on the sexual and reproductive health in arthritis care, the COVID-19 vaccine access and the COVID-19 Global Rheumatology Alliance. Register and join us for the Shared decision making webinar on April 25th to be hosted by Dr. Claire Barber, Dr. Glen Hazlewood and Dr. Karine Toupin April.

Newsletter – March 2021

This month we continue informing you about the rollout of the COVID-19 vaccine which is currently underway and what this means to many people living with rheumatic diseases. Read more.

When you live with arthritis,
information is your most important tool.

The Canadian Arthritis Patient Alliance (CAPA) works with various groups in the arthiritis community to ensure the voice of people living with arthritis is heard and to bring you up-to-date information on issues that affect the arthritis community. We work with healthcare professionals, health organizations, clinicians, industry, health charities, researchers, and various levels of government.

We keep Canadian people living with arthritis and their support groups understand more about their disease and have a voice in managing it.